A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness

Silvia Pegoraro; Gloria Ros; Yari Ciani; Riccardo Sgarra; Silvano Piazza; Guidalberto Manfioletti

doi:10.18632/oncotarget.4236

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness

Silvia Pegoraro, Gloria Ros, Yari Ciani, Riccardo Sgarra, Silvano Piazza and Guidalberto Manfioletti _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:19087-19101. https://doi.org/10.18632/oncotarget.4236

Metrics: PDF 3305 views | HTML 3638 views | ?

Abstract

Silvia Pegoraro1,*, Gloria Ros1,*, Yari Ciani1,2, Riccardo Sgarra1, Silvano Piazza2 and Guidalberto Manfioletti1

1 Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy

2 Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste, Italy

* These authors have contributed equally to this work

Correspondence to:

Guidalberto Manfioletti, email:

Silvano Piazza, email:

Keywords: cyclin E2, YAP/TAZ, hippo pathway, CDK inhibitors, oncogene/tumour suppressor

Received: October 20, 2014 Accepted: May 12, 2015 Published: May 22, 2015

Abstract

High Mobility Group A1 (HMGA1) is an architectural chromatin factor that promotes neoplastic transformation and progression. However, the mechanism by which HMGA1 exerts its oncogenic function is not fully understood. Here, we show that cyclin E2 (CCNE2) acts downstream of HMGA1 to regulate the motility and invasiveness of basal-like breast cancer cells by promoting the nuclear localization and activity of YAP, the downstream mediator of the Hippo pathway. Mechanistically, the activity of MST1/2 and LATS1/2, the core kinases of the Hippo pathway, are required for the HMGA1- and CCNE2-mediated regulation of YAP localization. In breast cancer patients, high levels of HMGA1 and CCNE2 expression are associated with the YAP/TAZ signature, supporting this connection. Moreover, we provide evidence that CDK inhibitors induce the translocation of YAP from the nucleus to the cytoplasm, resulting in a decrease in its activity. These findings reveal an association between HMGA1 and the Hippo pathway that is relevant to stem cell biology, tissue homeostasis, and cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4236

Publication Alerts

Research Papers:

A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness

Abstract